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The relationship between total homocysteine (tHcy) and dementia risk remains controversial, as the association varies among
populations and dementia subtypes. We studied a Venezuelan population that has high prevalence of both elevated tHcy and
dementia. We tested the hypotheses that (1) elevated tHcy is associated with increased dementia risk, (2) the risk is greater
for vascular dementia (VaD) than for Alzheimer’s disease (AD), and (3) a history of stroke may partly explain this association.
2100 participants (≥55 years old) of the Maracaibo Aging Study underwent standardized neurological, neuropsychiatric, and
cardiovascular assessments. Elevated tHcy was signiﬁcantly associated with dementia, primarily VaD. When history of stroke and
other confounding factors were taken into account, elevated tHcy remained a signiﬁcant risk factor in older (>66 years), but not
in younger (55–66 years) subjects. Ongoing studies of this population may provide insight into the mechanism by which tHcy
increases risk for dementia.
Copyright © 2009 Inara J. Chac´ on et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Hyperhomocysteinemia has been linked to a number of
pathological changes in the endothelium and small vessels
[1–6]. Oxidized metabolites of homocysteine have been
associated with intraneuronal accumulation of amyloid-
β (Aβ) 42 and neurotoxicity [7, 8]. These changes have
been proposed as the underlying mechanism explaining epi-
demiological observations that moderate elevation of total
plasma homocysteine (tHcy) is associated with an increased
risk of cardiovascular and cerebrovascular disease [9]a n d
dementia [10, 11]. However, the relationship between tHcy
and dementia is complex, because tHcy levels vary with
sex and age [12–14] and are inﬂuenced by diet (including
folate intake), lifestyle, health status, history of medication,
and genetic factors [12, 15–18]. Risk of dementia increases
with age and is inﬂuenced by many of the same factors
[19]. The interaction of these multiple variables makes it
diﬃcult to discriminate the independent contribution of
tHcy to dementia risk. Moreover, because most previous
studies examined subjects who were 65 years of age or
older [10, 20–22], those studies lacked a suﬃciently broad
age range necessary to distinguish the eﬀects of age from
that of elevated tHcy. In addition, most research examining
tHcy as a risk factor for dementia has been carried out in
developed countries [10, 23–27]; few studies have addressed
this issue in populations of Hispanic descent residing in
the developing world, particularly in Latin America, where2 International Journal of Alzheimer’s Disease
dietary supplementation with folate and multivitamins is
uncommon [28, 29].
In the current study, we examined the association
between tHcy level and risk of dementia in an elderly
population residing in the Caribbean city of Maracaibo,
Venezuela. This population oﬀers an opportunity to evaluate
the association between tHcy level and dementia risk,
becauseithasahighpr evalenc eofdementia[30],meantHcy
levels that are substantially higher than those in the U.S. or
Europe [14], and limited dietary and medical interventions
to prevent or treat hyperhomocysteinemia [28, 31]. In
addition,thestudyparticipantsincludedindividuals55years
of age and older, providing information about tHcy as a risk
factor for dementia in an age range that has not been well
studied. Speciﬁcally, the present study tested the hypotheses
that (1) high tHcy is related to increased risk of dementia;
(2) the risk is greater for vascular dementia (VaD) than
for Alzheimer’s disease (AD), and (3) a history of stroke,
representing a major cerebrovascular disease event, may be
part of the pathway explaining this association.
2.MaterialsandMethods
2.1. Participants and Setting. Subjects were participants in
the Maracaibo Aging Study (MAS), a population-based
cohort study that is investigating age-related diseases among
2437 elderly residents of the community of Santa Lucia,
Maracaibo, Venezuela [32]. The present study includes only
baseline cross-sectional data for the 2100 subjects that had
tHcy measurements. Sex and age distributions, educational
level, frequency of traditional cardiovascular risk factors
(CVRFs), and prevalence of dementia did not diﬀer signif-
icantly between the evaluated group and the 337 subjects
without tHcy measurements (data not shown). Information
on hypercholesterolemia, diabetes, smoking status, hyper-
tension, and stroke was not available for analysis in a small
percentage of cases, due to the facts that reliable information
could not be obtained, that some subjects did not respond
to certain questions, or that some assays failed. However,
the proportion of individuals with missing values was not
signiﬁcantly diﬀerent among demented or nondemented
participants. The University of Zulia Institutional Ethical
Review Board approved the MAS, and informed consent was
obtained from all participants.
2.2. Clinical Evaluation. The clinical evaluation included a
full battery of neuropsychiatric examinations that integrated
medical and family history with history of risk factors
for dementia. Standardized cardiovascular evaluation, nutri-
tional assessment, and neuropsychological testing were also
performed for every participant. For participants with
dementia, information concerning risk factors was obtained
from family informants. Methods are described in detail
elsewhere [30]. A diagnosis of dementia was determined
by consensus in a diagnostic conference of physicians,
psychologists, and social workers, based on the criteria in
the Diagnostic and Statistical Manual of Mental Disorders
(4th edition) [33]. AD was diagnosed following the criteria
of the NINCDS/ADRDA [34]. The criteria of the State of
California Alzheimer’s Disease Diagnostic and Treatment
Centers (ADDTC) [35] were used for diagnosis of VaD. The
ADDTC criteria require evidence of two or more ischemic
strokes (at least one infarct outside the cerebellum) by
history,neurologicalsigns,and/orneuroimagingstudies(CT
or T1-weighted MRI), or a single stroke with an evident
temporal relationship between the stroke and onset of
dementia. In the absence of a deﬁned stroke, clinical and
neuroimaging evidence for Binswanger’s disease is suﬃcient
to make the diagnosis of possible VaD. History of stroke was
t a k e nf r o ms e l f - r e p o r t s ,w h i c hd e ﬁ n e ds t r o k ea sa na c u t e
neurological deﬁcit lasting more than 24 hours that required
medical assistance.
2.3. Laboratory Analyses. Plasma tHcy, vitamin B12, and
folate were measured using blood samples obtained between
7:00 and 8:00 AM, after overnight fasting. All blood samples
were obtained and processed at the Cardiovascular Center
of the University of Zulia (CCUZ) in Maracaibo. Samples
were immediately placed in crushed ice and protected from
light and were processed within one hour of collection. The
biochemical assays for all samples were performed at the
CCUZ. As a quality control measure, a subset of samples
(n = 40) was tested at the University of Texas Southwestern
Medical School, using a method based on that of Araki and
Sako [36]. Apolipoprotein E(APOE) was genotyped using a
modiﬁed version [37] of the technique described by Hixson
and Vernier [38] . Details of sample collection and analyses
have been previously published [14].
2.4. Statistical Analysis. Means for demographic character-
istics were compared using t-tests, and diﬀerences in the
distribution of cardiovascular risk factors between groups
(e.g., demented versus nondemented) were evaluated using
the Pearson χ2 test. Levels of tHcy, vitamin B12, and folate
werelog-transformedtoﬁtnormaldistributions.Oddsratios
(ORs) and 95% conﬁdence intervals (CI) were calculated
using two logistic regression models. Model 1 adjusted for
age, sex, education, diabetes, folate, vitamin B12, and APOE
genotype. Model 2 adjusted for a history of stroke, in
addition to all of the covariates in Model 1. The latter model
was designed to assess whether stroke was an intermediate
factor [39], that is, a factor in the pathway in the relationship
between tHcy and dementia [5, 9, 40]. Therefore, Model 2
was intended to determine if the association between tHcy
and dementia was partly mediated by stroke [41].
We conducted analyses relating tHcy level to the risk of
dementia for the entire population, and also for two age
groups diﬀerentiated using the median age of the entire
sample (66 years) as the cut point. This was done to assess
the eﬀect of elevated tHcy on the risk of dementia in
individuals between 55 and 66 years of age, since this age
range is not usually studied. We also added an interaction
term to the logistic regression model to evaluate a possible
interaction between age group and tHcy. For this purpose,
tHcy ≥14μmol/L was used to deﬁne hyperhomocysteinemia
[10].International Journal of Alzheimer’s Disease 3
Table 1: Characteristics of the Maracaibo Aging Study population.
Characteristics All Demented Not demented
Population, no. (% females) 2100 (67.0) 169 (74.0) 1931 (66.4)
Age, mean (SD), y 67.2 (9.0) 77.8 (8.6)
∗∗ 66.3 (8.3)
Illiteracy, N (%) 298/2100 (14.2) 61/169 (36.1)
∗∗ 237/1931 (12.3)
Education, mean (SD), y 5.6 (4.0) 3.2 (3.2)
∗∗ 5.8 (4.0)
Hypercholesterolemia, N (%) 711/1553 (45.8) 49/121 (40.5) 662/1432 (46.2)
Diabetes, N (%) 287/2099 (13.7) 32/169 (19.0)
∗ 255/1930 (13.2)
Current smoker, N (%) 350/2100 (16.7) 20/169 (12.0) 329/1931 (17.0 )
Hypertension, N (%) 1739/2100 (82.8) 141/169 (83.4) 1598/1931 (82.8)
Stroke, N (%) 113/2099 (5.4) 40/169 (23.7)
∗∗ 72/1930 (3.7)
Hyperhomocysteinemia, N (%) 844/2100 (40.2) 117/169 (69.2)
∗ 727/1931 (37.6)
tHcy, mean (SD), mol/L 14.2 (6.3) 18.6 (7.5)
∗ 13.9 (6.0)
Folate, mean (SD), (ng/ml) 5.3 (2.9) 4.8 (3.3)
∗ 5.3 (3.0)
Vit B12, mean (SD), (pmol/ml) 416.9 (335.0) 426.3 (341.5) 415.9 (334.5)
APOE allele frequency
ApoE-ε2 0.046 0.035 0.047
ApoE-ε3 0.838 0.769 0.842
ApoE-ε4 0.116 0.166
∗ 0.111
∗P<. 05; ∗∗P<. 001, between demented and not demented groups.
Finally,weevaluatedtHcyasariskfactorfortheprincipal
formsofdementia,ADandVaD.Todothis,weusedonlyAD
or VaD cases and eliminated individuals suﬀering from other
forms of dementia or from mixed AD and VaD. All statistical
analyses were performed using SPSS software, Version 12
(SPSS Inc., Chicago).
3. Results
3.1. Population Characteristics. Mean age of participants was
67.2 years (Table 1). The ratio of women to men was 2 : 1
for the entire study population. Men were slightly younger
than women and had higher levels of education. Women
weremorelikelytohavehypercholesterolemia,andmenwere
more likely to be current smokers. Hypertension, deﬁned as
systolic blood pressure ≥140mmHg and diastolic pressure
≥90mmHg, was highly prevalent in this population, com-
pared to published reports for other Hispanic populations:
84.0% in this study versus 66.4% in the Northern Manhattan
Study [21]. The prevalence of self-reported stroke was 5.4%.
Frequency of the allele ε4 of the Apolipoprotein E gene
(ApoE-ε4) was 12% (Table 1).
3.2. Demented versus Nondemented Individuals. The overall
prevalenceofdementiawas8%(Table 1).Dementedindivid-
uals were signiﬁcantly older than nondemented individuals
(77.8 versus 66.3 year, resp.), had fewer years of formal
education(3.2versus5.8years),lowerfolatelevels(4.8versus
5.3ng/mL), and higher tHcy levels (18.6 versus 13.9μmol/L,
P<. 05 in all cases) (Table 1). Prevalence of hypertension,
current smoking, and hypercholesterolemia did not diﬀer
between demented and nondemented individuals; however,
the prevalence of diabetes (19.0 versus 12.6%) and of stroke
(23.7 versus 3.7%) was signiﬁcantly higher (P<. 01 in
both cases) in demented individuals than in nondemented
individuals.FrequencyoftheApoE-ε4allelewassigniﬁcantly
higher in demented individuals (16.6 versus 11.1%, P<. 01).
3.3. Homocysteine, Stroke, and Risk of Dementia. The overall
prevalence of hyperhomocysteinemia (tHcy ≥ 14μmol/L)
was high (40.2%) in this cohort (Table 1). Demented indi-
viduals were twice as likely as nondemented individuals to
have hyperhomocysteinemia (69.4 versus 37.6%, χ2 = 64.9,
P<. 0001).
When all subjects were examined together, each unit
increase in log-transformed tHcy level corresponded to a
fourfold increase in the risk for dementia after adjustments
for age, sex, education, diabetes, folate, vitamin B12, and
APOE genotype (Table 2,M o d e l1 ) .A d j u s t m e n tf o rs t r o k e
history (Model 2) had little eﬀect on the odds ratio (OR) for
the total study population.
When the sample was stratiﬁed into two age groups,
the unadjusted ORs for dementia associated with tHcy
were similar for individuals 55–66 years and for individuals
>66 years (Table 2) .W h e na d j u s t e df o ra g e ,s e x ,e d u c a t i o n ,
diabetes, APOE genotype, folate, and vitamin B12 (Model
1), the ORs remained signiﬁcant for both age groups, but the
OR for the younger group was slightly higher than that for
the older group (6.3 versus 4.2).
Stroke was strongly associated with dementia in both
age groups (unadjusted OR = 11.6, 95% C.I. = 4.5–29.7
for the younger group; OR = 7.3, 95% C.I. = 4.3–12.3
for the older group, P<. 001), even after adjustment for
sex,age,education,diabetes,APOEgenotype,folate,vitamin
B12, and tHcy (OR = 22.5., 95% C.I. = 6.0–84.4 for the
younger group; OR = 7.5, 95% C.I. = 4.0–14.0 for the
older group). When adjusted for stroke, the OR for dementia
associated with tHcy was relatively constant for individuals4 International Journal of Alzheimer’s Disease
Table 2: Odds ratios (ORs) for risk of dementia associated with log-transformed levels of total homocysteine (tHcy).
Number Crude Number Model 1a Number Model 2b
Group Risk factor Cases/Total OR 95% CI Cases/Total OR 95% CI Cases/Total OR 95% CI
Total sample log(tHcy) 169/2100 6.3
∗∗ 4.2–9.3 152/1787 4.2
∗∗ 2.4–7.3 152/1786 3.6
∗∗ 2.0–6.4
55–66 years log(tHcy) 23/1094 4.6
∗ 1.7–12.3 21/927 6.3
∗ 1.6–24.6 21/927 4.5 0.9–20.5
>66 years log(tHcy) 146/1006 4.7
∗∗ 2.9–7.5 131/860 4.2
∗∗ 2.3–7.8 131/859 3.8
∗∗ 2.0–7.2
aM o d e l1a d j u s t e df o ra g e ,s e x ,e d u c a t i o n ,d i a b e t e s ,A P O Eg e n o t y p e ,f o l a t e ,a n dv i t a m i nB 1 2 ;bModel 2 adjusted for age, sex, education, diabetes, APOE
genotype, folate, vitamin B12, and stroke, ∗P ≤ .02; ∗∗P<. 001.
Table 3: Comparison of risk associated with total homocysteine (tHcy) for Alzheimer’s disease (AD) and vascular dementia (VaD).
No. Crude No. Adjusted
a
Group Risk factor Cases/Total OR 95% CI Cases/Total OR 95% CI
AD log(tHcy) 74/2005 4.3
∗ 2.5–7.5 65/1701 1.9 0.9–4.2
VaD log(tHcy) 48/1979 7.8
∗ 4.1–15.1 45/1681 4.6
∗ 2.0–11.1
aAdjusted model includes age, sex, education, diabetes, folate, vitamin B12, and APOE genotype; ∗P ≤ .001, criteria from the NINCDS/ADRDA [34]w e r e
used to diagnose AD and criteria from the ADDTC [35] to diagnose VaD.
>66 years (Table 2, Model 2). However, the OR for the
younger group was reduced two folds and was no longer
statistically signiﬁcant, suggesting that stroke is acting as a
mediator between elevated tHcy and dementia.
For the total study population, 74 cases of dementia were
clinically classiﬁed as AD, and 48 as VaD. After adjusting for
covariates,elevatedtHcywasasigniﬁcantriskfactorforVaD,
but not for AD (Table 3).
4. Discussion
Hyperhomocysteinemia is a signiﬁcant risk factor for
dementiaintheMaracaiboAgingStudypopulation.Elevated
tHcy was associated with a fourfold increase in dementia risk
in both younger and older age groups, and the magnitude
of risk was even higher in younger than in older subjects.
Thus, the relationship between tHcy and dementia exists
over a broad age range. However, our results suggest that
a history of stroke mediates the relationship between tHcy
and dementia, and that this eﬀect may decline with age.
When stroke history was considered (Table 2, Model 2), the
magnitude of dementia risk associated with elevated tHcy
was reduced in the younger group, but not in the older
group. The reduced risk in the younger group suggests
that elevated tHcy may inﬂuence the risk of dementia by
increasing the risk of cerebrovascular disease and stroke-
related deﬁciencies, corroborating previous reports [25, 27,
42]. In other words, stroke may be an intermediate factor
[39] in the disease-causing pathway of tHcy. Alternatively,
elevated tHcy and stroke may act as independent risk factors,
with the inﬂuence of stroke overwhelmingly stronger than
that of tHcy. To test this hypothesis, we will need to
examine the temporality, which cannot be determined from
the present cross-sectional study. Our ongoing longitudinal
study of the MAS population will test this hypothesis.
In addition to disclosing age-related changes in the
relationship between hyperhomocysteinemia and dementia,
results of the present study showed that risk for VaD related
to tHcy was much higher than risk for AD (Table 3), further
supporting the role of cerebral vascular pathways [1, 4–
6, 9, 22]. The relationship between hyperhomocysteinemia
and AD is controversial [10, 27, 43]. Recent studies have
suggested that tHcy is a marker of coexisting vascular
conditions, rather than a direct risk factor for AD [44–46].
The overall role of elevated tHcy as a risk factor for stroke
and dementia is still unclear. A trial of supplementation
of vitamins B6 and B12 and folate showed no apparent
beneﬁt to the secondary prevention of stroke [47]. A clinical
trial using the same supplements for participants ≥65 years
of age with tHcy ≥ 13μmol/L found lower tHcy levels
in the treatment group after two years, but no diﬀerences
in cognition [48]. However, meta-analysis of clinical trials
suggested that longer treatment with folate is associated
with improvement in stroke risk [49] ,a n dt h i sn e e d st ob e
explored in relation to dementia.
One limitation of our study is its cross-sectional nature,
restricting our inferences about causality. Longitudinal
data from the ongoing MAS will provide further insight
into the mechanisms involved in the relationship between
hyperhomocysteinemia and dementia. The inclusion of a
younger cohort allowed us to examine the inﬂuence of
tHcy in preclinical stages; however, as expected, the younger
cohort had a relatively small number of dementia cases (23
out of 1094 participants), resulting in a large conﬁdence
interval. Therefore, the observed diﬀerences between age
groups should be interpreted with caution. Finally, our
clinical deﬁnition of stroke did not include data on “silent”
cerebrovascular disease from brain imaging, so prevalence of
cerebrovascular disease may have been underestimated.
To the best of our knowledge, the present study provides
one of the ﬁrst assessments of elevated tHcy as a risk
factor for dementia for individuals of Hispanic descent living
under the nutritional and environmental conditions of a
developing country. The only other study in populationsInternational Journal of Alzheimer’s Disease 5
of Latin America published to date simply examined the
correlation between tHcy level and MMSE value but did
not diagnose subjects as demented or diﬀerentiate between
diﬀerent types of dementia [29]. The Maracaibo Aging Study
is well suited to addressing some of the limitations observed
in earlier reports on the relationship between tHcy and
dementia. The MAS includes a large subject population of
individuals with similar genetic background and lifestyle,
and for the most part, unexposed to diﬀerent forms of
interventionsandtreatments.Thus,therelationshipbetween
tHcy and dementia in this population may be less aﬀected by
confounding factors. By studying a relatively homogeneous
population, some of the inconsistencies of the earlier studies
on heterogeneous populations are reduced. Earlier studies
included diverse ethnic groups with varying environmental
exposures: epidemiologic studies of Caucasian populations
in the U.S. and Great Britain [10, 22], and a study of His-
panics residing in North America [24] did ﬁnd a signiﬁcant
correlation between tHcy levels and dementia, while a study
of a multiracial community in Manhattan [21] did not.
In some cases, the association was attributed to vitamin
deﬁciencies, rather than to eﬀects of elevated tHcy [20]. In
the current study of the MAS population, the association
found with dementia was independent of folate and vitamin
B12 levels.
5. Conclusions
Thepresentstudyexaminedtheassociationbetweenelevated
tHcyanddementiaoverabroaderagerangethanmostprevi-
ous population-based studies. Although arbitrarily selected,
the age cut point allowed evaluation of the association of
tHcy and dementia in a signiﬁcant number (1094) of rela-
tively young individuals (55–66 years). Although longitudi-
naldataareneededtoassesscausality,thedemonstratedrela-
tionship between tHcy and dementia in the two age groups
of this Latin American population provides new insight into
the impact of hyperhomocysteinemia throughout life, and
into the relevance of tHcy as a risk factor in populations
from developing countries, where hyperhomocysteinemia is
common.
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